Cholecystokinin (CCK) and schizophrenia: the selective CCK B antagonist LY262691 decreases midbrain dopamine unit activity

Autor: Rasmussen, Kurt, Stockton, Marsha E., Czachura, Janet F., Jeffry Howbert, J.
Zdroj: In European Journal of Pharmacology 1991 209(1):135-138
Databáze: ScienceDirect